NEW YORK (GenomeWeb) – Bluebee has closed a Series A financing round in which it raised €10 million ($11.6 million) from new investors including Capricorn ICT Arkiv, Korys, and Biover II, and from existing shareholders including Buysse & Partners and the Bluebee management team.
The Dutch informatics firm plans to use the funds to further develop its cloud-based genomic analysis platform, which combines distributed computing capabilities with accelerated hardware to help customers process large volumes of genomic data quickly and efficiently.
"This is an exciting time for Bluebee," CEO Hans Cobben said in a statement. "After a successful market introduction in the second half of 2014, and with a rapidly growing customer base, the time is right to shift gears. This funding will significantly boost our capacity to support our growth. We appreciate the continued support of our existing shareholders, and look forward to working with our new investors."
Bluebee has also tapped Annie Vereecken to serve as chairman of its board of advisors, the company said. Vereecken is the founder and former owner of the AML-Labo Riatol labs, which was sold to Sonic Healthcare in 2010.
Last year, Bluebee raised €1.8 million in financing from Buysse & Partners and Delft University of Technology.